Freestone Grove Partners LP Takes $7.10 Million Position in Celcuity, Inc. $CELC

Freestone Grove Partners LP purchased a new stake in Celcuity, Inc. (NASDAQ:CELC) in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund purchased 67,907 shares of the company’s stock, valued at approximately $7,104,000. Freestone Grove Partners LP owned 0.14% of Celcuity at the end of the most recent quarter.

A number of other large investors have also added to or reduced their stakes in the stock. PNC Financial Services Group Inc. raised its holdings in Celcuity by 20.1% in the 1st quarter. PNC Financial Services Group Inc. now owns 514 shares of the company’s stock valued at $59,000 after acquiring an additional 86 shares in the last quarter. EverSource Wealth Advisors LLC lifted its position in shares of Celcuity by 15.1% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 944 shares of the company’s stock valued at $99,000 after acquiring an additional 124 shares during the period. US Bancorp DE grew its holdings in shares of Celcuity by 25.4% during the 3rd quarter. US Bancorp DE now owns 706 shares of the company’s stock worth $35,000 after purchasing an additional 143 shares in the last quarter. Intech Investment Management LLC grew its holdings in shares of Celcuity by 1.4% during the 4th quarter. Intech Investment Management LLC now owns 12,983 shares of the company’s stock worth $1,295,000 after purchasing an additional 183 shares in the last quarter. Finally, Aristides Capital LLC grew its holdings in shares of Celcuity by 2.0% during the 4th quarter. Aristides Capital LLC now owns 15,303 shares of the company’s stock worth $1,526,000 after purchasing an additional 303 shares in the last quarter. Institutional investors and hedge funds own 63.33% of the company’s stock.

Analysts Set New Price Targets

CELC has been the subject of a number of analyst reports. Leerink Partners set a $155.00 price target on Celcuity in a research note on Tuesday, June 2nd. Stifel Nicolaus reduced their price objective on shares of Celcuity from $175.00 to $150.00 and set a “buy” rating on the stock in a research note on Friday, August 14th. Wall Street Zen downgraded shares of Celcuity from a “sell” rating to a “strong sell” rating in a research note on Saturday, August 15th. Weiss Ratings upgraded shares of Celcuity from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, June 4th. Finally, Wells Fargo & Company dropped their target price on shares of Celcuity from $183.00 to $166.00 and set an “overweight” rating for the company in a research report on Wednesday, June 3rd. Ten research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $154.55.

Celcuity Price Performance

CELC stock opened at $88.44 on Friday. The company has a 50 day simple moving average of $94.64 and a 200 day simple moving average of $107.15. The stock has a market cap of $4.33 billion, a price-to-earnings ratio of -20.57 and a beta of 0.20. Celcuity, Inc. has a 1 year low of $44.42 and a 1 year high of $151.02. The company has a debt-to-equity ratio of 6.04, a current ratio of 8.93 and a quick ratio of 8.93.

Celcuity (NASDAQ:CELC) last issued its earnings results on Thursday, August 13th. The company reported ($1.44) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.16) by ($0.28). Research analysts anticipate that Celcuity, Inc. will post -4.75 EPS for the current fiscal year.

About Celcuity

Celcuity, Inc is a clinical-stage biotechnology company specializing in precision oncology diagnostics. The company develops and commercializes predictive biomarker assays designed to identify which patients are most likely to benefit from targeted cancer therapies. By integrating functional profiling of tumor cells with molecular analyses, Celcuity seeks to optimize treatment selection and improve outcomes for patients with solid tumors.

Celcuity’s proprietary platform evaluates tumor cell sensitivity to various therapeutic agents using ex vivo assays that measure DNA damage response and other critical pathways.